• History
• Mission
• Strategy
• Organization
  • Management
  • Board of Directors
  • Scientific Board
• Key Activities

Senior Management

Jens Fogh, DVM

President
Chief Executive Officer
Hillerød, Denmark

is a co-founder of Zymenex A/S and company President and CEO since June 1998.

Prior to co-founding Zymenex A/S, Dr. Fogh was with Novo Nordisk for 15 years, where he held positions as Director in R&D, as International Project Manager and Director in Marketing and as Director of Development Quality Assurance. His experience includes Preclinical and Clinical Development, Protein Production, International Marketing and Contract Negotiations as well as International Regulatory Affairs. In his capacity as Director, Dr. Fogh built up and managed large staffs and had close collaborations with NN affiliates and Pharmaceutical Companies around the world. As an ICH delegate, he worked together with representatives of the Pharmaceutical Industry and many International Regulatory bodies as EFPIA representative on several ICH guidelines.

Dr. Fogh holds a degree in Veterinary Medicine from the Royal Veterinary and Agricultural University, Copenhagen, and has over 30 publications in the fields of cancer, hemophilia and enzyme replacement therapy research.

Team Management

Claes Andersson, PhD

Research Director
Stockholm, Sweden

Dr. Andersson has been employed at Zymenex A/S since 1999 as Manager of Biochemistry and has been responsible for the development of several purification processes, analytical methods including scale-up and transfer to CMO’s and CRO’s. He has also contributed to the identification of new potential projects.

Prior to joining Zymenex, Dr Andersson has held positions as scientist, Project Manager and group- and section Manager at Pharmacia & Upjohn, Sweden. He has been responsible for the development of new analytical methods for some of P&U’s recombinant protein projects and also for building up the company’s proteomics platform.

Dr. Andersson holds a PhD degree in Biochemistry from Stockholm University and Karolinska Institute, Sweden and is the author of several patents and publications within the field of recombinant proteins.

Carl Eistrup, DVM, MBRT

Pre-clinical Director
Hillerød, Denmark

Dr. Eistrup has been employed at Zymenex since 2001 as Manager of Pharmacology and Toxicology. Prior to joining Zymenex Dr. Eistrup has participated as non-clinical coordinator in many drug development project groups that have been instrumental in bringingseveral Biotechnology Derived Pharmaceuticals within Diabetes and Hemophilia from Discovery to World Wide Marketing in his 17 years in positions as Toxicologist at Novo Nordisk.

Carl Eistrup holds a degree in Veterinary Medicine from Royal Veterinary and Agricultural University, Copenhagen. He is a Member of the British Register of Toxicologists, a EuroTox Registered Toxicologist and a Member of the American Society of Toxicology. He has formerly been a member of the non-clinical working groups for guidelines development within ICH and EFPIA.

Pia Ringholm, MSc Pharm

Quality Director
Hillerød, Denmark

Mrs. Ringholm joined Zymenex A/S in 2000 as Manager of Quality Assurance.

Mrs. Ringholm has 12 years experience from QA, Formulation Development, Quality Control and Aseptic Production in the Pharmaceutical Industry from positions in production and as Manager of Quality Control at the State Serum Laboratory, as Manager of Pharmacy at Leo Pharmaceuticals and from Christian Hansen.

Pia Ringholm has been responsible for planning, developing and managing quality assurance systems, has worked closely with authorities and representatives from the pharmaceutical industry as well as international contractors with regards to GMP, GLP and GCP. Mrs. Ringholm serves as a Qualified Person.

Mrs. Ringholm holds a Master of Science in Pharmacy from the Royal Danish School of Pharmacy, Copenhagen.